Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Lori Reilly

Lori Reilly Lori M. Reilly is Chief Operating Officer, providing executive level management, leadership and strategic direction at the Pharmaceutical Research and Manufacturers of America (PhRMA). In this role, Ms. Reilly oversees PhRMA’s Advocacy activities, including its federal, state, and international government affairs and alliance development work. Ms. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients. Ms. Reilly, named by the Hill as a top lobbyist in 2018, has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Ms. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions. Ms. Reilly has nearly two decades of experience at PhRMA; prior to her current role, Ms. Reilly was the Executive Vice President of Policy, Research, and Membership at PhRMA, leading the development and implementation of legislative, regulatory, and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee. Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln where she graduated with Honors, and a J.D. from the University of Nebraska College of Law. She is currently resides in Alexandria, Virginia with her husband and their four children.

Recent Posts

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

By Lori Reilly  |    December 9, 2022
With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “The Post-Midterm Health Care Agenda,”...   Read More

Report: More than 600 medicines in development for diseases affecting women

By Lori Reilly  |    March 31, 2022
As we approach the end of celebrating Women’s History Month, we’re taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women’s health.   Read More

PhRMA awards $75,000 to fund initiatives to reduce health inequities

By Lori Reilly  |    July 1, 2021
As part of PhRMA’s continuing commitment to build a more just and equitable health care system, we recently awarded $75,000 through our Collaborative Actions to Reach Equity (CAREs) grant program to...   Read More

In combating COVID-19, science is how we get back to normal

By Lori Reilly  |    June 24, 2020
America’s biopharmaceutical companies are working around the clock to combat a common enemy: COVID-19. As the fight to research and develop innovative treatments and vaccines advances, I’m pleased to...   Read More

PhRMA awards $100,000 to fund projects that address health inequalities

By Lori Reilly  |    June 10, 2020
As part of PhRMA’s continuing work to address health inequalities, we are awarding $100,000 total in grants to fund four projects that will help improve health outcomes by addressing inequity in...   Read More

Event: New era of medicine comes to Capitol Hill

By Lori Reilly  |    April 30, 2019
Biopharmaceutical researchers work every day to translate science into new treatments and cures. This passion has led to breakthroughs like gene therapy to treat childhood blindness, immuno-oncology...   Read More

Putting 2014 Figures on Prescription Drug Spending in Context

By Lori Reilly  |    April 14, 2015
Last year was unique for our nation’s health care system. Nearly 10 million uninsured patients gained health insurance coverage – the largest gain in four decades -- and the FDA’s Center for Drug...   Read More

Which 340B Entities Are Getting Most of the Savings?

By Lori Reilly  |    March 19, 2015
When policymakers think about the 340B program, they often think of the thousands of clinics that depend on the 340B program to help underserved populations. The 340B program requires pharmaceutical...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates